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Abstract
Purpose Breast cancer is a leading cause of cancer mortality in developed countries. We performed a meta-analysis of
randomized clinical trials to investigate the e ect of metformin on biomarkers associated with breast cancer outcomes and to
explore the dose–response relationship.
Methods A systematic search was performed from onset of the database to January 2019 in MEDLINE/PubMed, SCOPUS, and
Cochrane library to identify randomized clinical trials investigating the impact of metformin on insulin, glucose, CRP, leptin, body
mass indices (BMI), cholesterol, Ki-67, and Homeostatic Model Assessment for Insulin-Resistance (HOMA-IR). E ect sizes were 
expressed as weighted mean di erence (WMD) and 95% confidence intervals (CI) using a random-e ects models. Results Nine 
studies providing 1,363 participants were included in the meta-analysis. Pooled results showed a significant reduction in insulin
(WMD: − 0.99 U/ml, 95% CI − 1.66, − 0.33), glucose (WMD: − 1.78 ml/dl, 95% CI − 2.96, − 0.60), CRP (WMD: − 0.60 mg/l,
95% CI − 0.88, − 0.33), HOMA-IR (WMD: − 0.45, 95% CI − 0.77, − 0.11), leptin (WMD: − 2.44 ng/ml, 95% CI − 3.28, − 1.61),
2
BMI (WMD: − 0.55 kg/m , 95% CI − 1.00, − 0.11), and Ki-67 (WMD: − 4.06, 95% CI − 7.59, − 0.54). Results of the subgroup
analyses showed that insulin, glucose, and BMI decreased more significantly when the duration of administering metformin
intervention was above 4 weeks. We did not observe non-linear changes in the dose–response relationship between metformin and
biomarkers as outcomes.
Conclusions Breast cancer patients receiving metformin as treatment for diabetes showed significant reduction in levels
of insulin, fasting glucose, CRP, HOMA, leptin, BMI, and Ki-67.
Keywords Metformin · Breast cancer · Ki-67 · Insulin · Glucose · BMI
Introduction
Globally, breast cancers are the second most common occur-ring cancers (1.7 million cases, 11.9% of all cancers) next to lung
cancer and ranks as the most common cancers among women [1]. According to cancer research UK, by 2030, the global incidence
of cancers has been estimated at 23.6 mil-lion new cases [2, 3]. It is the primary cause of mortality in developed countries and
the second in developing countries, where the majority of the cases are diagnosed at later stages [4–7].
Cancers affect the morphology of cells resulting in abnormal division which metastasize to form a tumor [5]. Breast tissue
consists of fatty, connective, and lymphatic tissues which assist mammary glands in the production of milk. Typically, in the initial 
stages, benign breast can-cers are asymptomatic with small size tumor size that are easy to treat by surgical excision, supporting
screening for early detection [8]. Biomarkers such as p53 gene, HER2, BRCA1 & BRCA2, Ki-67, MUC1, and cyclin D-1 are use-
ful for screening, di erentiating tumors, and predicting the response to the therapy [9]. From 2005 to 2014, the inci-dence of breast
cancer increased by 1.7%, 0.4%, and 0.3% per year among Asian/Pacific Islander, non-Hispanic black, and Hispanic women,
respectively. Thus, novel strategies needed to improve breast cancer outcomes and survival rates [10–12].
Furthermore, outcomes are poorer among patients with type-2 diabetes, which has been associated with a higher cancer risk
[13, 14]. There is evidence to suggest that certain diabetic medications such as metformin can modify can-cer risk reducing breast
cancer recurrence and mortality, whereas medications such as insulin and its secretagogues are associated with increased recurrence 
and mortality [15]. A number of observational studies have reported beneficial therapeutic e ects of metformin in preventing breast 
can-cer reoccurrence and as well as other cancers such as endo-metrial, lung, liver, gastric, and medullary thyroid cancer [16 –21].
The pathways for the e ects of metformin include the reduction of hepatic glucose production which increases hepatic fatty acid
oxidation, reducing inflammation, and improving peripheral insulin sensitivity [22– 24]. Collec-tively, this process seems to reduce 
circulating glucose and insulin levels. However, evidence to support the mechanism of action of metformin is yet to be confirmed
[25, 26]. This systematic review and dose–response meta-analysis attempts to summarize the results from existing evidence on the 
e ects of metformin on biomarkers associated with breast cancer outcomes such as on insulin, glucose, CRP, leptin, body mass
indices (BMI), cholesterol, Ki-67, and homeo-static model assessment for insulin-resistance (HOMA-IR).
Methods
    
 
             
   
 
 
 
           
             
             
               
           
            
       
 
  
 
            
            
        
             
             
              
            
          
 
 
          
 
          
           
         
         
            
             
              
               
               
              
              
          
              
           
         
 
 
Study design and search strategy
This systematic review was performed according to the preferred reporting items for systematic review and meta-analysis
(PRISMA) statements [27].
Search strategy
A systematic literature search was conducted by two inde-pendent reviewers (JR and HKV) in PubMed/MEDLINE,
Cochrane, and SCOPUS (from inception to January 2019). Randomized Control Trials (RCTs) evaluating the e ects of
metformin on biomarkers associated with breast cancer out-comes were considered for inclusion. Boolean search terms
(AND, OR, or NOT) were used to create a search strategy, combining search terms related to the exposure (metformin
therapy) and outcomes (biomarkers associated with breast cancer: insulin, glucose, CRP, leptin, BMI, cholesterol, Ki-67,
and HOMA). We adopted a specific approach when developing the search strategy, without using date or lan-guage 
restrictions. We report details of the search strategy in the supplementary, Table 1.
Selection criteria
The participant, intervention, comparison, and outcome (PICO) criteria was used to establish study eligibility. Two authors (JR 
and NM) independently reviewed the abstract of all articles to select eligible studies. Titles and abstracts obtained from each
database were stored in Endnote Refer-ence Manager X8© and duplicates were excluded using the Endnote function “remove
duplicates”. Two investigators (JR and NM) independently reviewed the full texts of rel-evant articles. The following inclusion
criteria were used: (1) studies on adult patients (age > 18 years) with breast cancer that reported data on exposure to metformin
therapy versus placebo; (2) RCT studies reporting results in the form of mean di erences (MD) with the 95% confidence intervals
(95% CI) or reporting sufcient results for these estimates to be derived. Exclusion criteria were as follows: (1) studies comparing
the efcacy of drugs not including metformin; (2) other types of cancers; (3) studies not reporting biomarkers
Table 1 Baseline characteristics of included studies in the meta-analysis
Studies Author Country Year Fol- Patients, n Mean Metformin Biomarker
low up, age, dose (mg/
years years day)
1 Patterson RE USA 2018 24 333 62 1500 Insulin, Glucose, CRP
2 Davis SR Australia 2018 52 83 56 1700 Insulin, Glucose, HOMA, BMI
3 Sadighi S Iran 2016 24 45 50 1500 Insulin, Glucose, CRP, HOMA, Ki-67
4 Ko KP Republic of Korea 2015 24 81 – 500 Insulin, Glucose, BMI, Cholesterol
5 Ko KP Republic of Korea 2015 24 81 – 1000 Insulin, Glucose, BMI, Cholesterol
6 Goodwin PJ Canada 2015 24 492 52 850 Insulin, Glucose, CRP, HOMA, Leptin, BMI
7 Kalinsky K USA 2014 2 66 56 1500 Insulin, Glucose, HOMA, Leptin, BMI,
Cholesterol, Ki-67
8 Bonanni B Italy 2012 4 196 52 1700 Insulin, Glucose, CRP, Cholesterol, Ki-67
9 Hadad S UK 2011 2 39 63 1000 Insulin, Ki-67
 
 
 
 
            
     
 
 
 
            
               
                
     
 
  
 
           
           
                
                 
              
                 
            
 
  
 
              
             
          
            
               
          
          
             
               
            
            
         
           
      
 
 
 
 
 
             
           
         
                      
    
 
 
  
 
            
              
               
             
             
                  
         
associated with breast cancer; (4) animal studies; (5) non-randomized study designs or designs without a placebo group; (6)
conference abstracts, commentaries, case reports, and reviews.
Data extraction
Two reviewers (JR and NM) independently extracted the data using a predefined data extraction form. Discrepan-cies were 
discussed and resolved by senior author (YZ). The information extracted included author, year of publica-tion, country,
geographic location, duration of follow-up, number of patients, mean age (years), metformin dose (mg/ day), and mean and
SD of outcome in baseline study and post-intervention.
Quality assessment
Studies included in this review were critically appraised using the Cochrane collaboration’s tool for quality assess-ment of
randomized control trials [28], which considers the following domains: selection bias (random sequence genera-tion and allocation
concealment), performance bias, detec-tion bias, attrition bias, reporting bias, and other sources of bias. Each study was classified
as having a low, high, or unclear risk of bias for each domain. A study was considered to be at low risk of bias if they fulfilled
three key criteria related to randomization, allocation concealment, and out-come assessor blinding, and each study was rated as
having good, fair, or poor quality according to the AHRQ Standards [28]. The quality of evidence for each study was considered
to be good quality when all the domains were rated as low and was classified as good quality study.
Statistical analysis
The e ects of metformin therapy on biomarkers associ-ated with breast cancer were measured by weighted mean di erence
(WMD) with the 95% CI. When the standard deviation (SD) of the mean di erence for studies was not reported, we calculated
the SD using the following for-mula: SD2 baseline + SD2 final − (2 R × SD baseline + SD final) [29]. The random- e ects 
model (DerSimonian and Laird method) was used to calculate the pooled weighted mean di erence (WMD). Heterogeneity
across studies was assessed using the Q test, and the I- squared and an alpha of 0.05 for statistical significance were used.
We used Cochrane thresholds recommendation for system-atic reviews [30]. We defined heterogeneity using the fol-lowing
2 2 2
criteria: I of 0–30% unimportant heterogeneity, I = 30–60% moderate, 50–90% substantial heterogeneity, and I = 75– 
100% high. We performed subgroup analysis to identify the probable source of heterogeneity among trials. Duration of
intervention (≤ 4 week or > 4 week) was considered as predefined source of heterogeneity. Sensitiv-ity analysis was
performed to investigate the e ect of each study on overall analysis. The likelihood of publication bias was determined using
Egger’s and begg’s weighted regression tests and funnel plot. The non-linear potential effects of metformin dosage (mg/day)
were examined using fractional polynomial modeling. Meta-regression was used to determine e ect of participant age on
inter-vention outcomes. All statistical tests were conducted using the STATA 14 (StataCorp LP, College Station, USA),
using a p value of 0.05 for statistical significance.
Results
We retrieved 249 articles using our search strategy (Sup-plemental Fig. 1). After removing duplicates, 197 articles were screened
at title and abstract using the study selection criteria. We excluded 179 articles and retrieved 18 poten-tially relevant studies for
full-text assessment of eligibility. Eight articles (9 studies) [31–38] fulfilled the inclusion cri-teria and were included in the meta-
analysis. Nine articles were excluded for the following reasons: (1) no RCT design (n = 3), (2) no human trial (n = 5), and (3) no
placebo (n = 2).
Study characteristics
Characteristics of studies are presented in Table 1. These studies were conducted in the US [35 , 37], Australia [32], Iran [38],
Republic of Korea [ 36], Canada [33], Italy [31], and UK [34]. Most studies were recent publications (between 2011 and 2018).
The sample size was 1363 partici-pants, ranging from 39 to 492. Mean dose of the metformin was 1250 mg/day (ranging from 500
to 1700 mg/day). Nine studies investigated the e ect of metformin compare to pla-cebo administered to patients with breast cancer
on levels of blood circulating insulin levels [31–38], eight on glu-cose [31–33, 35–38], four on CRP [31, 33, 37, 38], four on
HOMA [32, 33, 35 , 38], two on Leptin [33 , 35 ], five on BMI [32, 33, 35, 36], four on cholesterol [31, 35, 36], and four on Ki-
67 [31, 34 , 35 , 38]. Table 2 provides the quality assessment results of the studies.
 
 
    
 
               
           
    
 
 
       
        
              
         
              
             
           
         
         
           
          
         
           
           
              
         
           
           
          
         
               
         
 
 
   
 
               
           
                
      
             
         
              
        
            
                  
            
     
            
                    
           
            
             
    
 
         
              
          
            
                 
 
 
Risk of bias assessment
Two studies were judged to have fair quality [31, 33] (Table 2), three poor quality [34, 35, 38], and have good quality [32, 
36, 37]. Most studies were judged to be of poor quality due to inadequate randomization techniques and blinding of
participants as well as assessors.
\
Table 2 Quality of the studies
Study name Selection Selection bias Reporting Other bias Performance Detection bias Attrition bias AHRQ
bias random allocation bias selective other sources bias blinding blinding incomplete Standards
sequence concealment reporting of bias outcome data
generation
Bonanni, 2012 Unclear Unclear Low Low Unclear Unclear Low Fair quality
Goodwin, Unclear Unclear Low Low Low Low Low Fair quality
2015
Davis, 2018 Low Low Low Low Low Low Low Good quality
Hadad, 2011 Low Low Low High High High Low Poor quality
Kalinsky, Not applicable Not applicable Low High Not applicable Not applicable Low Poor quality
2014
Ko, 2015 Low Low Low Low Low Low Low Good quality
Ko, 2015 Low Low Low Low Low Low Low Good quality
Patterson, Low Low Low Low Low Low Low Good quality
2018
Sadighi, 2016 Not applicable Not applicable Low High Not applicable Not applicable Low Poor quality
Results of meta analysis
Nine studies provided a total of 1363 participants (interven-tion = 665 and control = 698) reported levels of insulin as an outcome 
measure. We combined the results using random-e ects model and found significant reductions in insulin levels following
metformin intervention (WMD: − 0.99 U/ ml, 95% CI − 1.66, − 0.33) (Fig. 1). There was significant heterogeneity among studies 
2
(p = 0.01, I = 59.8).
Eight studies providing a total of 830 participants (inter-vention = 647 and control = 675) reported glucose as an outcome
measure. We pooled data using a random-e ects model and showed that there was a significant reduction in blood glucose levels
in the metformin group compared with the control group (WMD: − 1.78 ml/dl, 95% CI − 2.96,
2
− 0.60), with significant heterogeneity among studies (p = 0.09, I = 42.9).
Compared with placebo, metformin intervention was associated with a significant reduction in CRP levels (WMD: − 0.60 mg/l,
2
95% CI − 0.88, − 0.33) with no indication of heterogeneity among the studies (p = 0.73, I = 0.00).
For HOMA, the combined e ect size was − 0.45 (95% CI − 0.73, − 0.13) with no indication of sufcient heterogeneity
2
among the studies (p = 0.20, I = 33.9).
Results from a random-e ects model indicated that met-formin intervention resulted in significant reduction in leptin (WMD: −
2
2.44 ng/ml, 95% CI − 3.28, − 1.61 with no indi-cation of heterogeneity between studies (p = 0.61, I = 00.0).
Five studies providing 803 participants (case = 359, and control = 391) reported BMI as an outcome measure. We pooled
data using a random-e ects model and showed that BMI reduced in the metformin group compared with the control group
2
(WMD: − 0.55 kg/m , 95% CI − 1.00, − 0.11). There was no indication of significant heterogeneity among studies (p = 
0.17, I = 41.2).
We combined results from four studies using a random-e ects model. The results indicated that metformin interven-tion
demonstrated a non-significant reduction in cholesterol levels (WMD: − 6.80 mg/dl, 95% CI − 15.23, 1.64) with sig-nificant 
2
heterogeneity among the studies (p = 0.04, I = 62.5).
We also combined results from four numbers of stud-ies using a random-e ects model. For Ki-67, the combined e ect size was
2
− 4.06 (95% CI − 7.59, − 0.54), with sig-nificant heterogeneity between studies (p = 0.01, I = 79.1).
2 
  
 
 
 
              
                 
              
            
            
         
              
           
               
     
 
 
Subgroup analysis
Results of the subgroup analyses are summarized in Table 3. We stratified studies based on duration of metformin inter-
vention (≤ 4 and > 4 week). The results of the subgroup analyses showed that insulin levels (WMD: − 0.78 U/ml, 95% CI −
2
1.26, − 0.30), glucose levels (WMD: − 2.39 mg/ dl, 95% CI − 3.73, − 1.04), and BMI (WMD: − 0.58 kg/m , 95% CI − 1.09,
− 0.08) decreased more significantly when the duration of administering metformin intervention was above 4 weeks
compared with trials with less than 4-week duration (see Fig. 1).
We performed subgroup analyses for cholesterol lev-els. The results showed that cholesterol levels (WMD: − 13.03
mg/dl, 95% CI − 19.35, − 6.71) decreased signifi-cantly when metformin intervention duration was less than 4 weeks
compared with trials with above 4-week duration (WMD: 1.34 mg/dl, 95% CI − 6.95, 9.63).
We did not perform subgroup analysis for CRP, HOMA, leptin, and Ki- 37, because duration of interventions between
studies was similar (see Fig. 1).
 
 
                            
 
                                     
 
                                     
 
                                         
 
 
    
                 
                           
 
 
    
                 
                          
 
 
   
                 
                          
 
 
   
                         
                                   
 
 
   
                     
                              
 
 
   
                 
                          
 
 
    
                 
                          
 
 
    
                 
                          
 
 
    
                 
                          
 
                           
 
                                 
 
                                
 
                                
 
                  
 
                            
 
                                     
 
                                     
 
                                     
 
 
    
                  
   
 
 
                       
 
 
    
                  
   
 
 
                       
 
 
   
                 
   
 
 
                      
 
 
   
                       
    
 
 
                            
 
 
   
                  
   
 
 
                       
 
 
    
                    
   
 
 
                         
 
 
    
                   
   
 
 
                        
 
 
    
                       
   
 
 
                             
 
                           
 
                                 
 
                     
 
                     
 
                 
   
                          
     
 
(a) Insulin
Study %
ID WMD (95% CI) Weight
Ko, K. P. (2015) 0.00 (-0.93, 0.93) 16.25
Ko, K. P. (2016) -0.60 (-1.45, 0.25) 17.12
Bonanni, B. (2012) -0.50 (-1.41, 0.41) 16.45
Hadad, S. (2011) -12.88 (-20.83, -4.93) 0.68
Kalinsky, K. (2014) -4.12 (-7.42, -0.82) 3.46
Sadighi, S. (2016) -2.51 (-4.36, -0.66) 8.40
Patterson, R. E. (2018) -1.12 (-2.20, -0.04) 14.64
Davis, S. R. (2018) -1.00 (-5.01, 3.01) 2.47
Goodwin, P. J. (2015) -0.86 (-1.41, -0.32) 20.52
Overall (I-squared = 59.8%, p = 0.011) -0.99 (-1.66, -0.33) 100.00
NOTE: Weights are from random effects analysis
-20.8 0 20.8
(b) Glucose
Study %
ID WMD (95% CI) Weight
Ko, K. P. (2015) -1.10 (-3.37, 1.17) 14.91
Ko, K. P. (2016) -5.50 (-9.78, -1.22) 6.19
Bonanni, B. (2012) -1.00 (-2.63, 0.63) 20.37
Sadighi, S. (2016) 0.22 (-5.67, 6.10) 3.58
Kalinsky, K. (2014) -0.06 (-2.51, 2.39) 13.70
Goodwin, P. J. (2015) -3.33 (-4.63, -2.04) 23.83
Patterson, R. E. (2018) -1.29 (-3.46, 0.88) 15.68
Davis, S. R. (2018) -4.16 (-12.86, 4.53) 1.74
Overall (I-squared = 42.9%, p = 0.092) -1.78 (-2.96, -0.60) 100.00
NOTE: Weights are from random effects analysis
-12.9 0 12.9
Fig. 1 Forest plot of randomized controlled trials investigating the e ects of Metformin on: a insulin; b glucose; c CRP; d HOMA; e leptin; f
BMI; g cholesterol; h Ki-67
   
 
 
 
           
 
            
 
                 
 
            
 
            
 
             
 
             
 
              
 
               
 
                 
 
                 
 
      
 
          
 
           
 
          
 
               
 
 
      
          
 
 
        
             
 
 
       
           
 
 
     
         
 
        
 
          
 
             
 
             
 
        
  
 
   
 
 
 
   
 
            
            
\
(c) CRP
Study %
ID WMD (95% CI) Weight
Bonanni, B. (2012) -0.61 (-1.01, -0.21) 47.67
Sadighi, S. (2016) -0.80 (-1.34, -0.26) 26.26
Patterson, R. E. (2018) -0.46 (-1.06, 0.14) 21.54
Goodwin, P. J. (2015) -0.10 (-1.41, 1.21) 4.53
Overall (I-squared = 0.0%, p = 0.730) -0.60 (-0.88, -0.33) 100.00
NOTE: Weights are from random effects analysis
-1.41 0 1.41
(d) HOMA
Study
ID WMD (95% CI)
%
Weight
Sadighi, S. (2016) -0.60 (-1.03, -0.17) 26.35
Kalinsky, K. (2014) -1.11 (-2.01, -0.21) 8.53
Davis, S. R. (2018) -0.31 (-1.36, 0.74) 6.42
Goodwin, P. J. (2015) -0.30 (-0.44, -0.16) 58.69
Overall (I-squared = 33.9%, p = 0.209) -0.45 (-0.73, -0.17) 100.00
NOTE: Weights are from random effects analysis
-2.01 0 2.01
Fig. 1 (continued)
Meta regression and non linear dose–responses
We explored the dose–response relationship between dose of metformin (mg/day) and outcome. We found a non-linear fashion
between biomarkers and dose of metformin Insulin (Pnonlinearity = 0.22), glucose (Pnonlinearity = 0.18),
 
 
 
              
       
             
          
  
CRP (Pnonlinearity = 0.82), HOMA (Pnonlinearity = 0.41), BMI (Pnonlinearity = 0.39), cholesterol (Pnonlinearity = 0.34), and Ki-
67 (Pnonlinearity = 0.30) (Supplemental Fig. 2).
We used meta-regression analysis to examine the vari-ation in treatment e ect of metformin based on age of participants.
The results of the meta-regression suggested that participants’ age was not a significant source of clinical heterogeneity
(Supplemental Fig. 3).
 
 
 
 
                  
 
                    
 
                        
 
   
           
                   
 
    
         
                 
 
                    
 
                    
 
                     
 
                      
 
    
 
               
 
                  
 
              
 
                    
 
 
         
               
 
 
         
               
 
 
         
               
 
 
         
               
 
 
            
                  
 
            
 
               
 
                
 
                
 
            
  
 
   
 
 
 
 
    
 
                  
           
(e) Leptin
Study %
ID WMD (95% CI) Weight
Kalinsky, K. (2014) -1.65 (-4.87, 1.56) 6.73
Goodwin, P. J. (2015) -2.50 (-3.36, -1.64) 93.27
Overall (I-squared = 0.0%, p = 0.617) -2.44 (-3.28, -1.61) 100.00
NOTE: Weights are from random effects analysis
-4.87 0 4.87
(f) BMI
Study %
ID WMD (95% CI) Weight
Ko, K. P. (2015) -0.40 (-1.23, 0.43) 18.58
Ko, K. P. (2016) 0.00 (-0.83, 0.83) 18.59
Kalinsky, K. (2014) -0.27 (-1.27, 0.73) 14.44
Goodwin, P. J. (2015) -0.90 (-1.08, -0.72) 47.99
Davis, S. R. (2018) -2.00 (-9.03, 5.03) 0.40
Overall (I-squared = 41.2%, p = 0.147) -0.55 (-1.00, -0.11) 100.00
NOTE: Weights are from random effects analysis
-9.03 0 9.03
Fig. 1 (continued)
Publication bias and sensitivity analysis
The Egger’s and Begg’s tests did not show any publication bias for BMI (p = 0.20, p = 0.97), cholesterol (p = 0.38, p = 
0.49), CRP (p = 0.36, p = 0.17), glucose (p = 0.79, p = 0.98), HOMA (p = 0.23, p = 0.98), Ki-67 (p = 0.56,
 
 
 
              
               
           
             
 
 
p = 1.00), and leptin ( p = 1.00, p = 0.31), respectively (Supplemental Fig. 4). However, there was a significant publication
bias for insulin (p = 0.04, p = 0.09). ‘Trim-and-fill’ method used for adjusting publication bias, but did not show potentially
missing studies for the meta-analyses of insulin. The results of the sensitivity analysis did not show significant di erences
beyond the limits of 95% CI between calculated SESs for metformin intervention stud-ies (Supplemental Fig. 5).
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(g) Cholesterol
Study %
ID WMD (95% CI) Weight
Ko, K. P. (2015) 2.00 (-9.39, 13.39) 23.25
Ko, K. P. (2016) 0.60 (-11.50, 12.70) 22.05
Bonanni, B. (2012) -11.00 (-18.97, -3.03) 29.68
Kalinsky, K. (2014) -16.50 (-26.90, -6.10) 25.02
Overall (I-squared = 62.5%, p = 0.046) -6.80 (-15.23, 1.64) 100.00
NOTE: Weights are from random effects analysis
-26.9 0 26.9
(h) Ki-67
Study
ID WMD (95% CI)
%
Weight
Sadighi, S. (2016) -11.64 (-18.11, -5.17) 16.64
Kalinsky, K. (2014) -6.12 (-13.20, 0.96) 14.97
Bonanni, B. (2012) 0.00 (-2.30, 2.30) 32.58
Hadad, S. (2011) -3.38 (-4.74, -2.02) 35.82
Overall (I-squared = 79.1%, p = 0.002) -4.06 (-7.59, -0.54) 100.00
NOTE: Weights are from random effects analysis
-18.1 0 18.1
Fig. 1 (continued)
  
            
            
           
                
      
 
              
            
            
          
 
            
          
          
            
           
      
            
               
                   
                
            
               
     
             
                
                 
               
                
           
               
             
               
              
             
            
               
                
                 
            
                
              
             
       
       
           
              
            
               
               
            
              
              
          
                  
             
            
          
Discussion
This systematic review aimed to estimate the e ect of met-formin intervention on biomarkers associated with breast cancer
outcomes. To the best of our knowledge, this is the first systematic review of randomized -controlled tri-als investigating
the e ects of metformin on biomarkers among diabetic patients with breast cancer. The results demonstrated that diabetic 
patients with breast cancer showed significant reductions in insulin, fasting glucose, CRP, HOMA, leptin, BMI, and Ki- 67
when receiving met-formin compared with the control group.
There was evidence from nine RCTs investigating the effects of metformin therapy among breast cancer patients The results
showed that metformin significantly reduces the level of circulating blood insulin. Metformin reduces the levels of blood
circulating insulin by improving insu-lin sensitivity, increasing insulin receptor tyrosine kinase activity, enhancing glycogen
synthesis, decreasing hepatic gluconeogenesis, and increasing the activity of GLUT4 glucose transporters [39, 40].
We pooled data from eight RCTs that administered metformin and observed a reduction in blood glucose con-centration through
its direct hypoglycemic e ect such as enhancing glycogen synthesis and decreasing hepatic gluco-neogenesis by enhancing the 
LKB1/AMP-activated protein kinase (LKB1/AMPK) pathway [40]. Chronic inflammation negatively impacts on the outcomes of
breast cancer by the inactivation of tumor suppressor genes and stimulating angi-ogenesis and antigenic factor
production [41–43]. When data were pooled from four studies [26, 31, 33, 38 ], metformin showed a beneficial e ect of
reducing CRP, a marker of chronic inflammation.
Metformin demonstrated no difference in effects on cholesterol levels for the intervention group compared to the control group.
However, this finding may have been due to heterogeneity between groups of patients included in the meta-analysis. A subgroup
analyses of the results by duration of intervention (< 4 weeks or > 4 weeks) showed a significant decrease of cholesterol levels in
studies that conducted less than 4 weeks. This is similar to results of a systematic review reported by Wul elé and colleagues. The
authors investigated the e ect of metformin on blood pres-sure, plasma cholesterol, and triglycerides in type 2 diabetes mellitus
patients, and showed that total cholesterol reduced when duration of intervention by metformin was less than 12 weeks compared
with longer interventions [44].
We performed subgroup analysis to evaluate the impact of duration of metformin on insulin concentration, blood glucose, and
BMI. Significant improvements were observed at > 4 weeks of metformin therapy. Reductions in the weighted mean di erence of
blood glucose were observed with comparisons of < 4 weeks and > 4 weeks’ duration of metformin therapy, favoring interventions 
administered for longer durations. Participants receiving care for > 4 weeks showed glucose reductions which was twice as high
com-pared to metformin therapy of lesser duration. This pattern of improvement at > 4 weeks was observed for HOMA, lep-tin,
BMI, and Ki-67. This suggests that treatment for longer duration was associated with significant improvement in clinical outcome. 
However, for cholesterol concentration, better outcomes indicated by WMD: − 13.03 mg/dl (95% CI − 19.35, − 6.71) were
observed with the administration of metformin for a shorter duration of < 4 weeks.
Cancer cells have an underlying pathophysiology of increasing the level of blood circulating insulin and over stimulating
signaling pathways of IGF, leading to exces-sive growth of cancerous cells [45]. Metformin demon-strates its therapeutic e 
ect through its direct and indirect mechanisms, reducing insulin resistance and providing optimum glycemic control in breast
cancer patients [46]. Metformin acts by inhibiting the mTOR pathway; activat-ing autonomous AMP-activated protein
kinase (AMPK), leading to phosphorylation of tuberous sclerosis complex protein 2. This leads to a decrease in protein
synthesis and cell growth of cells [47–50]. Metformin reduces the levels of HOMA and leptin, higher concentration of which
is associated with poor outcomes. Leptins are believed to act on the OB-2 receptor leading to activation of STAT signaling
pathway and other pathways involving Ras–Raf MEK signaling. Metformin indirectly reduces the levels of
leptins, inhibiting OB- 2 receptor pathway. Other suggested mechanisms of action through which Metformin exerts its
indirect anti-cancerous e ect are by increasing TUNEL, a marker for apoptosis and reduces Ki-67, a marker of prolif-eration
[47, 51]. Furthermore, metformin demonstrates its weight loss e ect by improving mediators of insulin resist-ance, regulating
fat oxidation, decreasing hepatic glucose output, and inhibiting gluconeogenesis. This improves blood glucose control, 
decreasing food consumption and intestinal glucose absorption [52–54].
There is a conflicting evidence from the previous reviews evaluating the e ects of metformin among dia-betic breast 
cancer patients. A meta- analysis of observa-tional studies by Nandana et al. [18 ] assessed Metformin and breast cancer
risk. The authors reported a significant protective e ect of metformin on breast cancer risk among diabetic women [OR 0.83
(95% CI 0.71–0.97)] [18 ]. This is supported by findings by Pamela and colleagues where the intervention study showed
improvement in insulin lev-els, HOMA, leptins, and CRPs with metformin therapy [55]. This is, however, inconsistent with
results from a similar meta -analysis of observational studies conducted by Tang and colleagues assessing the e ect of
metformin in breast cancer incidence and mortality. The authors found no association between metformin therapy among
diabetic breast cancer patients and concluded that there is need for evidence from more rigorous study designs to investigate
the e ects of metformin on the survival rates in breast cancer [56]. Similarly, Bonanni et al. reported no significant decrease 
in Ki- 67 among patients receiv-ing metformin [31]. This is in contrast to findings of our meta-analysis suggesting beneficial
anticancer e ects of metformin among diabetic breast cancer patients. Overall, the findings of this review showed that 
metformin reduces the insulin concentration improving glycemic control, and reduces levels of HOMA -IR, Leptin, Ki-67,
and CRP, which improves outcome of increased survivals among breast cancer patients.
           
             
                
            
             
              
           
                 
          
       
 
 
 
 
             
                
             
              
             
  
 
 
 
This meta-analysis has several strengths and limitations. The main strength of the study is the use of randomized-
controlled trials as the study design of choice to investigate the association between the intervention and outcome. We
explored sources of heterogeneity among studies included in this meta-analysis, using subgroup analysis based on dura-tion
of interventions, age of participants and dose of met-formin, and performed sensitivity analysis.
However, there were some limitations to the study. Although we conducted a comprehensive search to reduce bias, we did not
perform hand searching of journals; hence, some studies may have been missed. Although we evalu-ated our studies using a robust 
quality assessment tool, these judgements were qualitative and inter-rater reliabilities were not explored. Another limitation of this
study is the small number of studies available for subgroup analysis of the e ect of metformin on most biomarkers. Larger studies
with adequate sample size are needed to inform definitive conclu-sions. We were reliant on data from significantly heterogene-ous
studies that were found to be at high risk of bias.
Conclusions
The results of this showed that metformin intervention sig-nificantly reduces insulin, fasting glucose, CRP, HOMA-IR,
leptin, BMI, and Ki- 67 levels among breast cancer patients. Greater reductions in insulin, glucose, and BMI where observed
when the duration of intervention was ≥ 4 weeks. However, changes in cholesterol levels were not observed and quality of
the evidence from this review was poor. We suggest that cautions were interpreting the findings of this review as most
studies demonstrated high risk of bias. We recommend that evidence from robust studies with long-term follow-up is needed
to make definitive clinical recommendations.
  
 
        
      
      
      
      
       
         
        
     
     
       
         
        
     
     
       
         
        
     
     
       
         
         
     
     
       
         
      
     
     
       
         
        
     
     
       
         
        
     
     
       
         
        
     
      
 
 
 
 
 
Variables Duration (week) All (–)
≤ 4 > 4
Insulin
Number of studies 3 6 9
Weighted mean di erence (WMD) − 4.35 − 0.78 − 0.99
95% CI − 9.28, 0.57 − 1.26, − 0.30 − 1.66, − 0.33
p-heterogeneity 0.01 0.24 0.01
Glucose
Number of studies 2 6 8
Weighted mean di erence (WMD) − 0.71 − 2.39 − 1.78
95% CI − 2.07, 0.64 − 3.73, − 1.04 − 2.96, − 0.60
p-heterogeneity 0.53 0.21 0.09
CRP
Number of studies 1 3 4
Weighted mean di erence (WMD) − 0.61 − 0.60 − 0.60
95% CI − 1.01, − 0.20 − 0.98, − 0.21 − 0.88, − 0.33
p-heterogeneity – 0.52 0.73
HOMA
Number of studies 1 3 4
Weighted mean di erence (WMD) − 1.11 − 0.33 − 0.45
95% CI − 2.01, − 0.21 − 0.46, − 0.19 − 0.73, − 0.17
p-heterogeneity – 0.42 0.20
Leptin
Number of studies 0 2 2
Weighted mean di erence (WMD) – 2.20 − 2.44
95% CI – 1.60–3.04 − 3.28, − 1.61
p-heterogeneity – 0.540 0.61
BMI
Number of studies 1 4 5
Weighted mean di erence (WMD) − 0.27 − 0.58 − 0.55
95% CI − 1.26, 0.72 − 1.09, − 0.08 − 1.00, − 0.11
p-heterogeneity – 0.13 0.14
Cholesterol
Number of studies 2 2 4
Weighted mean di erence (WMD) − 13.03 1.34 − 6.80
95% CI − 19.35, − 6.71 − 6.95, 9.63 − 15.23, 1.64
p-heterogeneity 0.41 0.86 0.04
Ki-37
Number of studies 3 1 4
Weighted mean di erence (WMD) − 2.39 − 11.64 − 4.06
95% CI − 5.33, 0.54 − 18.10, − 5.17 − 7.59, − 0.54
p-heterogeneity 0.02 – 0.01
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